Global Pleural Diseases Market Trends and Insights
Increasing Pleural Disease Incidence and Hospitalization
Pleural diseases associated with lung cancer, heart failure, pneumonia, and tuberculosis continue to sustain hospital admissions across healthcare systems. Clinical evidence indicates that pleural effusion affects 320 to 1,300 people per million annually, while tuberculosis-related conditions account for 30% to 80% of pleural effusion cases in India. A 2026 survey of 414 respiratory physicians across 15 countries found that extrapulmonary disease affects 1 in 5 tuberculosis patients, with pleuritis identified as the most common form. Aging populations in North America, Europe, and East Asia also show a higher prevalence of cardiac and oncology-related conditions that cause recurrent effusions. The need for repeated assessment, drainage, and follow-up supports consistent demand for devices and consumables in the pleural diseases market.Expansion of Minimally Invasive and Outpatient Pleural Care
The shift from inpatient chest drainage to outpatient indwelling pleural catheter placement is reshaping pleural care delivery. Indwelling pleural catheters enable long-term management of symptomatic recurrent effusions outside hospital settings, including for patients with poor functional status or non-expandable lungs. A 2025 review described daily drainage protocols, outpatient talc slurry administration, and digital pump systems that can expand catheter use across a wider patient population. Intrapleural administration of chemotherapy agents or sclerosants through these platforms could extend their application beyond drainage. This care model reduces inpatient dependence while increasing demand for outpatient supplies, monitoring, and patient education.High Procedure Costs and Uncertain Reimbursement for Advanced Interventions
Cost and coverage differences between standard drainage procedures and advanced interventions can limit access to emerging pleural technologies. Artificial intelligence (AI)-guided imaging, implantable shunts, and intrapleural aerosol chemotherapy may require reimbursement decisions that fall outside established drainage payment codes. Retrospective evidence reported a pleurodesis success rate of 61.2% with thoracoscopic catheter placement, compared with 24.9% with percutaneous placement; however, thoracoscopic procedures incur higher costs. Pleural Dynamics reported that its ACES implantable shunt received a Centers for Medicare & Medicaid Services (CMS) reimbursement code in 2025 after presenting post-market study results at CHEST 2025. The gap between regulatory clearance and reimbursement can delay commercial adoption. In Asia-Pacific and Latin America, limited insurance coverage for thoracoscopic pleural services can restrict patient access and reduce the near-term reach of the pleural diseases market.Other drivers and restraints analyzed in the detailed report include:
- Wider Adoption of Immunotherapy and Combination Therapy for Pleural Mesothelioma
- Increasing Use of Tunneled Pleural Catheters and Specialist Pathways
- Limited Data, Diagnostic Delays, and Complex Care Requirements
Segment Analysis
Pleural drainage devices held 34.45% of the 2026 product-type segment, representing the largest share of the pleural diseases market. Their leadership reflects the widespread use of indwelling pleural catheters for malignant effusion management across oncology centers in North America, Europe, and higher-income Asia-Pacific countries. In October 2025, Foshan Fosun Chancheng Hospital performed the first PleurX catheter implantation in mainland China under the Hong Kong-Macao Medicine and Equipment Connect policy.This development demonstrates the geographic expansion potential of established drainage products. Catheter systems support recurring patient management needs, generate ongoing demand for related supplies, and enable follow-up care outside hospital settings. Surgical and interventional products are projected to grow at a CAGR of 10.24% through 2032, driven by the increasing use of video-assisted thoracoscopic surgery (VATS) for diagnostic biopsies and pleurodesis. The ACES implantable shunt achieved a median 53% reduction in effusion volume at 30 days, while 80% of patients required no additional drainage through 60 days.
Pleural effusion accounted for 44.93% of the 2026 disease-type segment and remained the largest component of the pleural diseases market. It is a common pleural syndrome across age groups and a primary treatment target for drainage devices, imaging, and therapeutic products. Recurrent effusion may occur with cancer, heart failure, liver disease, infection, and other chronic conditions, sustaining demand for thoracentesis, catheter placement, pleurodesis, and follow-up care.
Malignant pleural effusion also connects pleural procedures with oncology treatment pathways, while its broad range of causes diversifies demand across patient groups. Pleurisy is forecast to grow at a CAGR of 8.67% through 2032, supported by tuberculosis-associated pleuritis in Asia-Pacific and Africa. In the 2026 physician survey, 80.4% of respondents considered tuberculous pleuritis in the differential diagnosis for new-onset unilateral pleural effusion. Pneumothorax, pleural mesothelioma, empyema, chylothorax, and hemothorax also support ongoing procedural demand.
Complete Report Scope:
- By Product Type
- Pleural Drainage Devices
- Therapeutic Products
- Diagnostic Products and Systems
- Surgical and Interventional Products
- Others product Type
- By Disease Type
- Pleural Effusion
- Pleurisy
- Pneumothorax
- Pleural Mesothelioma
- Empyema
- Other Pleural Diseases
- By Diagnostic Tool
- Imaging Techniques
- Endoscopic and Surgical Diagnosis
- Laboratory and Molecular Diagnosis
- By End User
- Hospitals and Clinics
- Ambulatory and Outpatient Facilities
- Academic and Research Institutes
- Homecare Settings
- Other End Users
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 41.52% of the 2026 pleural diseases market share, supported by strong pulmonology capacity, established reimbursement pathways for indwelling pleural catheters, and significant mesothelioma treatment spending. The 2025 American Society of Clinical Oncology (ASCO) guideline supports several first-line systemic regimens for eligible patients with pleural mesothelioma. NovoCure reported USD 1.1 million in fourth-quarter 2025 revenue from Optune Lua for malignant pleural mesothelioma. The United States benefits from a large commercially insured population with access to checkpoint inhibitor combinations and specialized care. In Canada, publicly funded oncology centers support catheter use, while centralized thoracic surgery programs manage procedural costs. Mexico remains an emerging private-sector opportunity, with pleural services concentrated in major urban referral centers, while Food and Drug Administration (FDA) requirements for artificial intelligence (AI) diagnostic software influence imaging platform adoption.Asia-Pacific is projected to grow at a CAGR of 9.22% through 2032, the fastest rate in the pleural diseases market. China and India are expected to contribute substantially to incremental patient volume. In China, the first mainland PleurX implantation under the Hong Kong-Macao Medicine and Equipment Connect policy demonstrated a pathway for newer devices to reach patients. India has a high burden of tuberculosis-associated pleural disease, with tuberculosis accounting for 30% to 80% of pleural effusion presentations. This burden supports demand for diagnostic and drainage procedures in tertiary hospitals and tuberculosis control programs. Japan and Australia sustain higher-value procedural activity, including mesothelioma care associated with historical asbestos exposure. At the same time, Australia’s AMPLE, LENT, and AESOP studies continue to influence clinical practice beyond its domestic patient base.
Europe has an established pleural research base, with the United Kingdom contributing major catheter studies and specialist care pathways. Germany remains active in device adoption and mesothelioma treatment, accounting for 16 of NovoCure’s 27 Optune Lua prescriptions for malignant pleural mesothelioma in the fourth quarter of 2025. France, Spain, and Italy are centralizing pleural procedures in academic centers, improving access to specialized equipment. The Middle East and Africa face a significant burden of tuberculosis-related pleural disease and parapneumonic effusion, although diagnostic capacity varies outside Gulf Cooperation Council countries.
List of Companies Covered in this Report:
- AstraZeneca
- ATMOS MedizinTechnik
- B. Braun
- Beckton Dickinson
- Bristol-Myers Squibb
- Cook Group
- Eli Lilly and Company
- Genentech
- Getinge
- ICU Medical
- Medela
- Medtronic
- Merck
- Merit Medical Systems
- NovoCure Limited
- Pfizer
- Redax S.p.A.
- Rocket Medical plc
- Teleflex
- Vygon S.A.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca PLC
- ATMOS MedizinTechnik GmbH & Co. KG
- B. Braun SE
- Becton, Dickinson and Company
- Bristol-Myers Squibb Company
- Cook Group Incorporated
- Eli Lilly and Company
- Genentech, Inc.
- Getinge AB
- ICU Medical, Inc.
- Medela AG
- Medtronic plc
- Merck & Co., Inc.
- Merit Medical Systems, Inc.
- NovoCure Limited
- Pfizer Inc.
- Redax S.p.A.
- Rocket Medical plc
- Teleflex Incorporated
- Vygon S.A.

